Huang Zhiwei, Liu Zhihong, Luo Qin, Zhao Zhihui, Zhao Qing, Zheng Yaguo, Xi Qunying, Tang Yi
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Can J Cardiol. 2016 Nov;32(11):1356.e1-1356.e10. doi: 10.1016/j.cjca.2016.02.058. Epub 2016 Feb 23.
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction, vascular remodelling, and microthrombotic events. Inflammatory cytokine interleukin (IL-6) may be a key factor in the development of PAH, and glycoprotein 130 (Gp130) is an important signal-transducing subunit of IL-6. The aim of our study was to evaluate the effectiveness of Gp130 inhibitor in reducing inflammation and ameliorating PAH-related vascular remodelling in monocrotaline (MCT)-exposed rats.
Sprague-Dawley rats (n = 96; weight, 240-250 g) were randomly divided into 3 groups: control, MCT-exposed (MCT), and MCT-exposed plus Gp130 inhibitor (MCT-Gp) administered daily (5 mg/kg) from days 14-28. Eight rats were killed in each group at weeks 1 through 4, with the following measured variables compared across groups on day 28: hemodynamics, right ventricular hypertrophy, morphometric measurements, immunohistochemical results, levels of IL-6, phosphorylated signal transducer and activator of transcription 3, proliferating cell nuclear antigen (PCNA), bone morphogenetic protein receptor-2 (BMPR2), proangiogenic factor, vascular endothelial growth factor (VEGF), proproliferative kinase extracellular signal-regulated kinase (ERK), survivin, Bcl-2, and Bax.
Compared with the MCT group, Gp130 inhibitor, after MCT exposure, improved hemodynamics and significantly reduced the severity of inflammation, as estimated by levels of IL-6 (P < 0.0001), and reversed pulmonary arterial remodelling, as assessed by medial wall thickness (P < 0.0001). Gp130 inhibitor upregulated BMPR2 expression in MCT-exposed lungs (P = 0.040) and decreased the expression of PCNA, VEGF, ERK, and survivin (all P < 0.05).
Gp130 inhibitor upregulated BMPR2 expression in MCT-exposed lungs, restored the BMPR2/IL-6 balance, reduced IL-6-associated inflammation, inhibited pulmonary artery smooth muscle cell proliferation, and ameliorated pulmonary vascular remodelling in MCT-induced PH in rats.
肺动脉高压(PAH)的特征是血管收缩、血管重塑和微血栓形成事件。炎性细胞因子白细胞介素(IL-6)可能是PAH发生发展的关键因素,而糖蛋白130(Gp130)是IL-6的重要信号转导亚基。我们研究的目的是评估Gp130抑制剂在减少炎症和改善野百合碱(MCT)诱导的大鼠PAH相关血管重塑方面的有效性。
将96只Sprague-Dawley大鼠(体重240 - 250 g)随机分为3组:对照组、MCT诱导组(MCT)和MCT诱导加Gp130抑制剂组(MCT-Gp),从第14天至第28天每天给予Gp130抑制剂(5 mg/kg)。在第1至4周每组处死8只大鼠,在第28天比较各组的以下测量变量:血流动力学、右心室肥大、形态学测量、免疫组化结果、IL-6水平、磷酸化信号转导及转录激活因子3、增殖细胞核抗原(PCNA)、骨形态发生蛋白受体2(BMPR2)、促血管生成因子血管内皮生长因子(VEGF)、促增殖激酶细胞外信号调节激酶(ERK)、生存素、Bcl-2和Bax。
与MCT组相比,MCT暴露后给予Gp130抑制剂改善了血流动力学,并显著降低了炎症严重程度(以IL-6水平评估,P < 0.0001),逆转了肺动脉重塑(以内膜厚度评估,P < 0.0001)。Gp130抑制剂上调了MCT暴露肺组织中BMPR2的表达(P = 0.040),并降低了PCNA、VEGF、ERK和生存素的表达(均P < 0.05)。
Gp130抑制剂上调了MCT暴露肺组织中BMPR2的表达,恢复了BMPR2/IL-6平衡,减少了IL-6相关炎症,抑制了肺动脉平滑肌细胞增殖,并改善了MCT诱导的大鼠肺动脉高压中的肺血管重塑。